BR0212329A - Métodos para tratar doença pulmonar - Google Patents

Métodos para tratar doença pulmonar

Info

Publication number
BR0212329A
BR0212329A BR0212329-0A BR0212329A BR0212329A BR 0212329 A BR0212329 A BR 0212329A BR 0212329 A BR0212329 A BR 0212329A BR 0212329 A BR0212329 A BR 0212329A
Authority
BR
Brazil
Prior art keywords
methods
lung disease
treat lung
pulmonary
hemodynamics
Prior art date
Application number
BR0212329-0A
Other languages
English (en)
Inventor
Glenn J Smits
Francis G Spinale
Original Assignee
Biogen Idec Inc
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Musc Found For Res Dev filed Critical Biogen Idec Inc
Publication of BR0212329A publication Critical patent/BR0212329A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODOS PARA TRATAR DOENçA PULMONAR". Métodos úteis para reduzir a vasoconstrição pulmonar ou melhorar as hemodinâmicas pulmonares em um paciente são descritos. Mais particularmente, esta invenção refere-se à administração de antagonistas de receptor de adenosina A, para reduzir a vasoconstrição pulmonar e melhorar as hemodinâmicas pulmonares.
BR0212329-0A 2001-09-06 2002-09-06 Métodos para tratar doença pulmonar BR0212329A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31790801P 2001-09-06 2001-09-06
PCT/US2002/028580 WO2003022284A1 (en) 2001-09-06 2002-09-06 Methods of treating pulmonary disease

Publications (1)

Publication Number Publication Date
BR0212329A true BR0212329A (pt) 2004-09-21

Family

ID=23235775

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212329-0A BR0212329A (pt) 2001-09-06 2002-09-06 Métodos para tratar doença pulmonar

Country Status (20)

Country Link
US (1) US20040259889A1 (pt)
EP (1) EP1429775A4 (pt)
JP (2) JP4388373B2 (pt)
KR (1) KR100979738B1 (pt)
CN (1) CN1564688A (pt)
AU (1) AU2002341618B2 (pt)
BR (1) BR0212329A (pt)
CA (1) CA2459533A1 (pt)
EA (1) EA014684B1 (pt)
GE (1) GEP20074132B (pt)
HU (1) HUP0401805A3 (pt)
IL (1) IL160715A0 (pt)
IS (1) IS7163A (pt)
MX (1) MXPA04002135A (pt)
NZ (1) NZ532083A (pt)
PL (1) PL368935A1 (pt)
UA (1) UA80258C2 (pt)
WO (1) WO2003022284A1 (pt)
YU (1) YU20104A (pt)
ZA (1) ZA200401765B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0312137A (pt) * 2002-06-12 2005-04-05 Mcw Res Found Inc Processo de tratamento de dano de reperfusão de isquemia usando antagonistas de receptor de adenosina
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US7579331B2 (en) * 2003-04-25 2009-08-25 Novacardia, Inc. Method of improved diuresis in individuals with impaired renal function
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
MX2009000169A (es) 2006-06-23 2009-01-26 Incyte Corp Derivados de purinona como agonistas de hm74a.
TWI423977B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
EP2217233B1 (en) * 2007-10-26 2018-08-08 New York University School of Medicine Methods and compositions for treating hepatic diseases
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
US20100063071A1 (en) * 2008-06-13 2010-03-11 Kiesman William F Therapeutic compositions and related methods of use
KR20130088834A (ko) * 2010-06-30 2013-08-08 길리애드 사이언시즈, 인코포레이티드 폐 고혈압의 치료를 위한 ａ２ｂ 아데노신 수용체 길항제의 용도
JP2016516708A (ja) * 2013-03-14 2016-06-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ビシクロ［２．２．２］酸のｇｐｒ１２０モジュレーター
IL275817B2 (en) 2018-01-04 2024-04-01 Impetis Biosciences Ltd Tricyclic compounds, preparations and their medical applications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208240A (en) * 1991-03-12 1993-05-04 Merrell Dow Pharmaceuticals Inc. 8-substituted purines as selective adenosine receptor agents
TW252044B (pt) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
GB9723553D0 (en) * 1997-11-07 1998-01-07 Duff Gordon W Prediction of the risk of chronic obstructive airway disease
ZA9810766B (en) * 1997-11-28 1999-05-25 Mochida Pharm Co Ltd Novel compounds having cgmp-pde inhibitory activity
EP1044003A4 (en) * 1998-01-09 2000-12-27 Univ Pennsylvania COMPOSITIONS AND TREATMENTS SUITABLE FOR TISSUE LESIONS RELATED TO REPERFUSION OF ISCHEMIA OR DUE TO ENDOTOXINS
EP0970696A1 (en) * 1998-05-05 2000-01-12 Kyowa Hakko Kogyo Co., Ltd. Combination of loop diuretics with adenosine A1-receptor antagonists
CA2390496A1 (en) * 1999-11-12 2001-05-17 Biogen, Inc. Polycycloalkylpurines as adenosine receptor antagonists
AU784878B2 (en) * 1999-12-02 2006-07-13 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 A2A and A3 receptors and uses thereof

Also Published As

Publication number Publication date
NZ532083A (en) 2005-10-28
HUP0401805A2 (hu) 2004-12-28
IL160715A0 (en) 2004-08-31
PL368935A1 (en) 2005-04-04
JP2005501915A (ja) 2005-01-20
UA80258C2 (en) 2007-09-10
IS7163A (is) 2004-02-26
US20040259889A1 (en) 2004-12-23
ZA200401765B (en) 2005-04-05
EP1429775A4 (en) 2007-04-11
EA014684B1 (ru) 2010-12-30
EP1429775A1 (en) 2004-06-23
WO2003022284A1 (en) 2003-03-20
CN1564688A (zh) 2005-01-12
EA200400399A1 (ru) 2004-08-26
KR100979738B1 (ko) 2010-09-09
JP2009209156A (ja) 2009-09-17
YU20104A (sh) 2006-08-17
KR20040040457A (ko) 2004-05-12
GEP20074132B (en) 2007-06-25
AU2002341618B2 (en) 2008-06-26
JP4388373B2 (ja) 2009-12-24
HUP0401805A3 (en) 2007-05-02
CA2459533A1 (en) 2003-03-20
MXPA04002135A (es) 2005-03-07

Similar Documents

Publication Publication Date Title
BR0212329A (pt) Métodos para tratar doença pulmonar
BR0008447A (pt) Métodos de tratamento de distúrbios mitocondriais
NO20041070L (no) Preparat for behandling av vanlig forkjolelse.
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
CY1112560T1 (el) Πνευμονικη μεταφορα των αμινογλυκοσιδων
NZ522326A (en) Adenosine A2A receptor antagonists
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
WO2003094835A3 (en) Fgf variants and methods for use thereof
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
BR9812361A (pt) Uso de combinações compreendendo anti-histaminas não-sedantes e drogas alfa-adrenérgicas para o tratamento tópico de rinite/conjutivite e sintomas de infecção por vìrus, semelhante a infecção por vìrus e/ou resfriado
BR9913152A (pt) Terapias para tratamento de doenças pulmonares
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
DE60215000D1 (de) DIHYDROPYRROLOi1,2-AöINDOL- UND TETRAHYDROPYRIDOi1,2-AöINDOLDERIVATE ALS PROSTAGLANDIN REZEPTOR ANTAGONISTEN
NO20060871L (no) Azepinderivater som farmasoytiske midler
BRPI0417820A (pt) heterociclos azabicìclicos como moduladores de receptor canabinóide
BR0211450A (pt) Método terapêutico
BR9809951A (pt) Método para tratamento da obesidade
BR0107628A (pt) l,2-diarilbenzimidazóis para tratamento de doenças que estão associadas a uma ativação microglial
BR0213037A (pt) Derivados de pirimidina
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
MXPA04003910A (es) Uso de irbesartan para la preparacion de medicamentos que son utiles para la prevencion o tratamiento de hipertension pulmonar.
TWI256388B (en) Pharmaceutical combination
BR0011845A (pt) Complexo farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/52, A61K 31/522, A61K 45/00, A61P 11/00, A61P 9/12, C07D 473/06

Ipc: A61K 31/52 (2011.01)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2166 DE 10/07/2012.